Context: Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic
agent for malignant gliomas. Recently, TMZ has been documented to be effective against …

Pituitary tumors are amongst the most common intracranial neoplasms and are generally
benign. However, some pituitary tumors exhibit clinically aggressive behavior that is …

BACKGROUND AND IMPORTANCE: The case presented here describes the clinical
evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) …

Context The mechanisms of pituitary adenoma (PA) pathogenesis and proliferation remain
largely unknown. Objectives To clarify the role of mismatch repair (MMR) genes in the …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Temozolomide (TMZ) has recently been recommended as the first line chemotherapy in
patients with aggressive pituitary tumors (APT) and pituitary carcinomas (PC) not controlled …

Purpose: Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray
therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide. Recently …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Objective Aggressive pituitary tumours may be difficult to treat. Temozolomide (TMZ) is an
alkylating cytostaticum. In a small number of cases, TMZ therapy has been reported to …

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded
to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable …